TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›ASBP›Financials
Annual statements · SEC XBRL · FY2021 – FY2025

Aspire Biopharma Holdings, Inc. (ASBP) financials

Income statement

Aspire Biopharma Holdings, Inc. (ASBP) income statement, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Revenue————$6.20K
Gross profit————-$116.00
Gross margin————-1.9%
Operating income———-$1.21M-$19.4M
Operating margin————-312016.9%
Net income—$3.34M$4.46M-$1.31M-$24.5M
Net margin————-394725.1%
EPS (diluted)———-$1.90-$16.38

Cash flow

Aspire Biopharma Holdings, Inc. (ASBP) cash flow, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Operating cash flow—-$1.41M-$653K-$265K-$4.92M
Share buybacks——$285M$13.8M—

Balance sheet

Aspire Biopharma Holdings, Inc. (ASBP) balance sheet, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Cash & equivalents—$497K$11.2K$3.63K$1.00M
Total assets$293K$300M$20.0M$148K$1.31M
Total liabilities$294K$11.1M$403K$1.69M$7.69M
Shareholders' equity-$475.00-$9.94M-$488K-$1.54M-$6.38M
Retained earnings-$25.5K-$9.94M-$11.3M-$2.78M-$27.3M
Shares (wtd avg diluted)———690K1.49M

Every figure is extracted from Aspire Biopharma Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Aspire Biopharma Holdings, Inc.'s annual revenue?
Aspire Biopharma Holdings, Inc. (ASBP) reported $6.20K of revenue for fiscal year 2025, per its annual report filed with the SEC.
Is Aspire Biopharma Holdings, Inc. profitable?
Not in FY2025 — ASBP reported a net loss of $24.5M, per SEC filings.
Does ASBP pay a dividend?
Aspire Biopharma Holdings, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full ASBP analysis — verdict, score & filings →Is ASBP a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.